Research and standardization in Alzheimer's trials: Reaching international consensus

Maria C. Carrillo; Christopher C. Rowe; Cassandra Szoeke; Colin L. Masters; David Ames; Tim O'Meara; S. Lance Macaulay; Andrew Milner; Kathryn A. Ellis; Paul Maruff; Stephanie R. Rainey-Smith; Ralph N. Martins; Lisa J. Bain; Richard J. Head

doi:10.1016/j.jalz.2012.10.006

Research and standardization in Alzheimer's trials: Reaching international consensus

Maria C. Carrillo^*, Christopher C. Rowe, Cassandra Szoeke, Colin L. Masters, David Ames, Tim O'Meara, S. Lance Macaulay, Andrew Milner, Kathryn A. Ellis, Paul Maruff, Stephanie R. Rainey-Smith, Ralph N. Martins, Lisa J. Bain, Richard J. Head

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is an epidemic facing the entire world. Increased knowledge gained during the past 25 years indicates that AD falls along a clinical and neuropathological spectrum represented as a continuum that extends from preclinical disease in which there are no symptoms, through early symptomatic phases, and finally to AD dementia. The Alzheimer's research community recognizes that imaging, body fluids, and cognitive biomarkers contribute to enhanced diagnostic confidence for AD. There has also been emerging consensus regarding the use of AD biomarkers in clinical trials. The use of biomarkers in clinical trials and practice is hampered by the lack of standardization. In response to the emerging need for standardization, an international meeting of AD researchers was held in Melbourne, Australia, in March 2012 to bring together key researchers, clinicians, industry, and regulatory stakeholders with the aim of generating consensus on standardization and validation of cognitive, imaging, and fluid biomarkers, as well as lifestyle parameters used in research centers worldwide.

Original language	English
Pages (from-to)	160-168
Number of pages	9
Journal	Alzheimer's and Dementia
Volume	9
Issue number	2
DOIs	https://doi.org/10.1016/j.jalz.2012.10.006
Publication status	Published - Mar 2013
Externally published	Yes

Keywords

Alzheimer's disease
Amyloid imaging
Biomarkers
Cerebral spinal fluid
Clinical outcomes
Diagnosis
Early detection
Magnetic resonance imaging

Access to Document

10.1016/j.jalz.2012.10.006

Cite this

Carrillo, M. C., Rowe, C. C., Szoeke, C., Masters, C. L., Ames, D., O'Meara, T., Macaulay, S. L., Milner, A., Ellis, K. A., Maruff, P., Rainey-Smith, S. R., Martins, R. N., Bain, L. J., & Head, R. J. (2013). Research and standardization in Alzheimer's trials: Reaching international consensus. Alzheimer's and Dementia, 9(2), 160-168. https://doi.org/10.1016/j.jalz.2012.10.006

@article{9a35d320684c47a5a6d9823f3a939e6d,

title = "Research and standardization in Alzheimer's trials: Reaching international consensus",

abstract = "Alzheimer's disease (AD) is an epidemic facing the entire world. Increased knowledge gained during the past 25 years indicates that AD falls along a clinical and neuropathological spectrum represented as a continuum that extends from preclinical disease in which there are no symptoms, through early symptomatic phases, and finally to AD dementia. The Alzheimer's research community recognizes that imaging, body fluids, and cognitive biomarkers contribute to enhanced diagnostic confidence for AD. There has also been emerging consensus regarding the use of AD biomarkers in clinical trials. The use of biomarkers in clinical trials and practice is hampered by the lack of standardization. In response to the emerging need for standardization, an international meeting of AD researchers was held in Melbourne, Australia, in March 2012 to bring together key researchers, clinicians, industry, and regulatory stakeholders with the aim of generating consensus on standardization and validation of cognitive, imaging, and fluid biomarkers, as well as lifestyle parameters used in research centers worldwide.",

keywords = "Alzheimer's disease, Amyloid imaging, Biomarkers, Cerebral spinal fluid, Clinical outcomes, Diagnosis, Early detection, Magnetic resonance imaging",

author = "Carrillo, {Maria C.} and Rowe, {Christopher C.} and Cassandra Szoeke and Masters, {Colin L.} and David Ames and Tim O'Meara and Macaulay, {S. Lance} and Andrew Milner and Ellis, {Kathryn A.} and Paul Maruff and Rainey-Smith, {Stephanie R.} and Martins, {Ralph N.} and Bain, {Lisa J.} and Head, {Richard J.}",

year = "2013",

month = mar,

doi = "10.1016/j.jalz.2012.10.006",

language = "English",

volume = "9",

pages = "160--168",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Wiley-Blackwell, Wiley",

number = "2",

}

TY - JOUR

T1 - Research and standardization in Alzheimer's trials

T2 - Reaching international consensus

AU - Carrillo, Maria C.

AU - Rowe, Christopher C.

AU - Szoeke, Cassandra

AU - Masters, Colin L.

AU - Ames, David

AU - O'Meara, Tim

AU - Macaulay, S. Lance

AU - Milner, Andrew

AU - Ellis, Kathryn A.

AU - Maruff, Paul

AU - Rainey-Smith, Stephanie R.

AU - Martins, Ralph N.

AU - Bain, Lisa J.

AU - Head, Richard J.

PY - 2013/3

Y1 - 2013/3

N2 - Alzheimer's disease (AD) is an epidemic facing the entire world. Increased knowledge gained during the past 25 years indicates that AD falls along a clinical and neuropathological spectrum represented as a continuum that extends from preclinical disease in which there are no symptoms, through early symptomatic phases, and finally to AD dementia. The Alzheimer's research community recognizes that imaging, body fluids, and cognitive biomarkers contribute to enhanced diagnostic confidence for AD. There has also been emerging consensus regarding the use of AD biomarkers in clinical trials. The use of biomarkers in clinical trials and practice is hampered by the lack of standardization. In response to the emerging need for standardization, an international meeting of AD researchers was held in Melbourne, Australia, in March 2012 to bring together key researchers, clinicians, industry, and regulatory stakeholders with the aim of generating consensus on standardization and validation of cognitive, imaging, and fluid biomarkers, as well as lifestyle parameters used in research centers worldwide.

AB - Alzheimer's disease (AD) is an epidemic facing the entire world. Increased knowledge gained during the past 25 years indicates that AD falls along a clinical and neuropathological spectrum represented as a continuum that extends from preclinical disease in which there are no symptoms, through early symptomatic phases, and finally to AD dementia. The Alzheimer's research community recognizes that imaging, body fluids, and cognitive biomarkers contribute to enhanced diagnostic confidence for AD. There has also been emerging consensus regarding the use of AD biomarkers in clinical trials. The use of biomarkers in clinical trials and practice is hampered by the lack of standardization. In response to the emerging need for standardization, an international meeting of AD researchers was held in Melbourne, Australia, in March 2012 to bring together key researchers, clinicians, industry, and regulatory stakeholders with the aim of generating consensus on standardization and validation of cognitive, imaging, and fluid biomarkers, as well as lifestyle parameters used in research centers worldwide.

KW - Alzheimer's disease

KW - Amyloid imaging

KW - Biomarkers

KW - Cerebral spinal fluid

KW - Clinical outcomes

KW - Diagnosis

KW - Early detection

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=84875371210&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2012.10.006

DO - 10.1016/j.jalz.2012.10.006

M3 - Article

C2 - 23266004

AN - SCOPUS:84875371210

SN - 1552-5260

VL - 9

SP - 160

EP - 168

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 2

ER -

Research and standardization in Alzheimer's trials: Reaching international consensus

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this